Urokinase Versus Video-assisted Thoracoscopic to Treat Complicated Parapneumonic Empyema in Childhood
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00798278 |
Recruitment Status :
Completed
First Posted : November 26, 2008
Last Update Posted : October 28, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Empyema Pneumonia | Drug: Urokinase Procedure: Video-Assisted Thoracoscopic | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 200 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Exploratory Multicentre Clinical Trial to Compare the Efficacy of Urokinase Versus Video-assisted Thoracoscopic for Treatment of Complicated Parapneumonic Empyema in Childhood |
Study Start Date : | July 2008 |
Actual Primary Completion Date : | September 2010 |
Actual Study Completion Date : | September 2010 |

Arm | Intervention/treatment |
---|---|
Experimental: Urokinase
urokinase infusion for 3 days
|
Drug: Urokinase
Chest tube with intrapleural urokinase infusion for 3 days |
Active Comparator: Thoracoscopic
Video-Assisted Thoracoscopic
|
Procedure: Video-Assisted Thoracoscopic
Video-Assisted Thoracoscopic decortication |
- duration of the hospital stay after the treatment [ Time Frame: 3 months ]
- complications of the treatment and complications of the disease [ Time Frame: 3 months ]
- total duration of the hospital stay [ Time Frame: 3 months ]
- number of days carrying the chest drain [ Time Frame: 3 months ]
- duration of the fever once the empyema has been drained [ Time Frame: 3 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Year to 15 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients less than 15 years of age with pneumonia and persistent fever, and complicated parapneumonic empyema (septation or loculation seen on ultrasound or Rx thorax)stages II and III requiring an intervention to drain
Exclusion Criteria:
- Existing contraindications or other previous conditions, hypertension, pneumothorax

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00798278
Spain | |
Hospital Universitario Central de Asturias | |
Oviedo, Asturias, Spain | |
Hospital de Donostia | |
San Sebastián, Donostia, Spain, 20014 | |
University Hospital Vall d'Hebron | |
Barcelona, Spain, 08035 | |
Hospital Gregorio Marañón | |
Madrid, Spain | |
Hospital Infantil La Paz | |
Madrid, Spain | |
Hospital Universitario 12 de Octubre | |
Madrid, Spain |
Responsible Party: | Claudia Marhuenda Irastorza, University Hospital Vall d'Hebron. Barcelona |
ClinicalTrials.gov Identifier: | NCT00798278 |
Other Study ID Numbers: |
UKVATS2007 EudraCT Number 2007-003416-61 |
First Posted: | November 26, 2008 Key Record Dates |
Last Update Posted: | October 28, 2010 |
Last Verified: | November 2008 |
Empyema Urokinase Thoracoscopic Childhood |
Empyema Infections Suppuration Inflammation Pathologic Processes |